Navigation Links
Some Blood Pressure Drugs May Stave Off Dementia
Date:1/12/2010

Medications' role against angiotensin appears to be key, study finds,,

TUESDAY, Jan. 12 (HealthDay News) -- Blood pressure drugs that block the protein angiotensin appear to reduce the risk of developing Alzheimer's disease and other forms of dementia, a new study finds.

"We think it [angiotensin] is one of the most important factors determining healthy blood vessels and also acts in the brain to help neurons to be a little more resilient," said Dr. Benjamin Wolozin, a professor of pharmacology and neurology at Boston University and senior author of a report on the findings, published online Jan. 13 in BMJ.

That report describes a study of more than 819,000 U.S. veterans, nearly all men, that found that those taking blood pressure medications that block cell receptors for angiotensin had a lower risk for dementia than those taking other cardiovascular medicines.

A similar but smaller protective effect was found for a related drug, lisinopril (Prinivil, Zestril), which blocks production of the active form of angiotensin.

Angiotensin causes blood vessels to constrict, raising blood pressure. It is produced when enzymes act to convert a precursor molecule, angiotensinogen. Lisinopril is a member of a drug family called ACE (angiotensin-converting enzyme) inhibitors. Other examples of ACE inhibitors are benazepril (Lotensin), enalapril (Vasotec) and ramipril (Altace).

Reducing angiotensin production by giving ACE inhibitors can lower blood pressure. The same effect can be achieved with drugs that block the cell receptors through which angiotensin acts. Called angiotensin receptor blockers, these drugs have a greater protective effect against dementia than ACE inhibitors, the study found. Such drugs include candesartan (Atacand), irbesartan (Avapro), losartan (Cozaar) and valsartan (Diovan).

In the study, men taking an angiotensin receptor blocker had a 24 percent lower incidence of dementia than those taking other cardiovascular drugs. The risk was 19 percent lower for men taking ACE inhibitors. The risk was nearly halved for those taking both angiotensin-targeting drugs.

In men with Alzheimer's disease, use of an angiotensin receptor blocker reduced admission to nursing homes by half. Combined angiotensin medication therapy reduced nursing home admissions by two-thirds.

Wolozin said that it's not clear why the drugs would have a beneficial effect on the brain, but improved blood flow probably plays a role.

"If you get no blood to the brain, you're not going to think well," he said. "Also, in brain cells there is more than one kind of angiotensin receptor. By blocking bad receptors, you are left with the good ones so that helps neurons become more resilient."

But the evidence is not sufficient to support routine use of angiotensin receptor blockers to prevent Alzheimer's disease, Wolozin said. The new report describes an observational study, one that lacks the strict controls that are needed for convincing proof.

"Any study like this is hypothesis-generating," he said. "You only know for sure when you have done clinical prospective trials."

His advice for anyone considering angiotensin receptors blockers to reduce dementia risk: "They should consult with their physicians." There are potential hazards, such as too-low blood pressure that can lead to damaging falls, Wolozin said.

Caution was urged by Dr. Richard B. Lipton, vice chairman of neurology at Albert Einstein College of Medicine in New York City, who has done work on the genetics of Alzheimer's disease.

The angiotensin hypothesis makes sense, Lipton said, because improved blood flow to the brain helps nerve cells and reduces formation of Alzheimer's-related amyloid protein.

But there have been a number of observational studies implicating various molecules, including estrogens, in dementia, he said. "The sequence is that when you do the randomized trial, you don't get the same effect," Lipton said.

On the other hand, such randomized trials usually include people who are close to having Alzheimer's disease, and "it could be different if you gave the drugs earlier," Lipton said.

More information

The U.S. Food and Drug Administration has more on blood pressure medications.



SOURCES: Benjamin Wolozin, M.D., professor, pharmacology and neurology, Boston University School of Medicine, Boston; Richard B. Lipton, M.D., professor and vice chairman, neurology, Albert Einstein College of Medicine, New York City; Jan. 13, 2010, BMJ, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Specific antagonism lowers blood pressure
2. Restricting Blood Flow May Help Heart Bypass Patients
3. FDA Updates Prescription Guidelines for Blood Thinner
4. Doctors Often Miss High Blood Pressure in Kids
5. Back to School Means Return of School Blood Drives
6. Blood-flow detector software show promise in preventing brain damage
7. FDA Approves New Roche West Nile Virus Blood Screening Test
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Laser blasts viruses in blood
10. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
11. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... Coalition Duchenne, a Newport Beach, California based charity committed ... in the April 25 U.S. Food and Drug Administration advisory committee hearing on ... the Marriott Conference Center in Hyattsville, Maryland was attended by over than a ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Society for Assisted Reproductive ... are required to report in vitro fertilization (IVF) delivery rates to ... practice of assisted reproductive technologies in the United States. , This year, ...
(Date:4/29/2016)... ... 2016 , ... The number of chronically and seriously ill individuals is growing. ... an urgent need for highly skilled care managers and care coordinators. Care ... train and retain care managers, and enhance their skills. , Care Excellence ...
(Date:4/28/2016)... ... April 29, 2016 , ... Monthly subscription boxes are all the ... They recently reviewed the ZEN BOX , the aromatherapy subscription box. , ZEN ... oils (like lavender or frankincense) and one Zen Blend (like immune boost, sublime sleep ...
(Date:4/28/2016)... ... 2016 , ... Sanford Health’s work in cellular therapy and ... and leaders from Sanford Health were selected to participate in the “ Third ... and receive the 2016 Pontifical Key Innovation Award at the Vatican. , The ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... Transparency Market Research has published ... Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... skincare devices market was valued at US$ 7,255.8 Mn ... CAGR of 10.1% from 2015 to 2023 to reach ... full Skincare Devices Market (Treatment Device - LED Therapy Devices, ...
Breaking Medicine Technology: